Category: Stock Market

Picking three popular ASX blue chip shares is the easy part of this exercise.

The harder question is whether Commonwealth Bank of Australia (ASX: CBA), Macquarie Group Ltd (ASX: MQG), and CSL Ltd (ASX: CSL) can still justify their place in a portfolio two decades from now, not just today.

Each faces a genuine test over that horizon, and each currently looks like it can pass it, for different reasons.

Commonwealth Bank of Australia: the test is whether dominance survives disruption

CBA’s 20-year test is not whether it remains Australia’s largest bank. It has a good chance of it.

The real test is whether a dominant, capital-intensive incumbent can keep fending off digital disruption for two more decades, as it has for the past two.

In the first half of FY2026, CBA delivered a statutory net profit of $5.41 billion, up 5% on the prior corresponding period. Furthermore, CBA was able to continue ramping up technology spending to defend its lead.

However, at approximately 26 times forward earnings, CBA already prices in a significant amount of that continued dominance.

The bull case rests on scale, trust, and a banking app used by more Australians than any rivals. These advantages compound slowly but have proven durable across multiple banking cycles already.

Macquarie Group: the test is whether a trading culture can keep reinventing itself

Macquarie’s 20-year test is different again.

Unlike a retail bank, Macquarie has already reinvented its business model multiple times across three decades, moving from a niche investment bank into one of the world’s largest infrastructure and asset managers.

Morgans was impressed with Macquarie’s FY2026 performance. The broker noted profit was up strongly on the prior year and ahead of consensus estimates. However, the broker flagged that, following recent share price strength, Macquarie shares are close to being fully valued today.

Yet for long-term holders, the case for Macquarie over two decades is less about today’s price and more about betting on a management culture that has consistently found its next growth engine before the previous one matured. These intrinsic competitive advantages are harder to predict than a bank’s mortgage book, but ones Macquarie has repeatedly delivered on.

CSL: the test is whether execution catches up to the moat

CSL’s 20-year test is the most interesting of the three. This is because the moat is not in question, but the recent execution has been.

Morgans retains a buy rating on CSL with a price target of $147.59, arguing the issues behind the FY2026 guidance downgrade, including China albumin price pressure and US immunoglobulin channel inventory normalisation, are executional rather than structural.

CSL’s barriers to entry in plasma collection and biotherapeutics remain extremely high, built over more than a century of operating history. That durability is why brokers have remained broadly constructive even amid a 60% decline from its all-time high.

CSL shares now trade on roughly 28 times earnings, expensive but insignificant over a 20-year time horizon.

The 20-year case for CSL is essentially a bet that an irreplaceable global franchise outlasts a difficult few years of execution. This is the kind of mis-pricing that long-term holders are supposed to be able to look through.

Why the 20-year framing changes the analysis for these ASX shares

Most “buy and hold” investors default to a five-year horizon. This is where current earnings momentum and broker price targets carry most of the weight.

Stretching that horizon to 20 years shifts the question from “what will this stock do next year” to “does the underlying moat survive technological, competitive, and cyclical change for two decades.”

CBA’s moat is threatened by digital disruption. Macquarie’s moat depends on a culture of reinvention rather than a single fixed advantage. CSL’s moat is arguably the strongest of the three on paper, but is currently being tested by execution rather than competition.

Foolish takeaway for these ASX shares

CBA, Macquarie, and CSL each represent a different kind of 20-year bet.

CBA is a bet that scale and trust keep beating disruption. Macquarie is a bet that a culture of reinvention will continue to work as well in 2046 as it has since the 1990s. CSL is a bet that an already-proven moat outlasts a rough few years of execution.

With strong track records on reinforcing their respective competitive advantages, these three blue-chip ASX shares are positioned to continue delivering well into the future.

The post 3 ASX blue chip shares to buy and hold for the next 20 years appeared first on The Motley Fool Australia.

More reading

• Once untouchable, now unloved: What’s up with CSL shares?
• $10,000 invested in CSL shares 12 months ago is now worth…
• Why I’d buy CSL and Zip shares before they recover
• New to ASX shares? Avoid these 3 beginner mistakes
• 3 quality ASX shares I’d buy (that aren’t CBA or Wesfarmers)

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

WiseTech Global Ltd (ASX: WTC) shares have been smashed.

The logistics software company is trading around $31.39, down almost 75% from its 52-week high of $121.31.

That is a huge fall for a company that was once one of the ASX’s most highly rated technology shares. It also raises a fair question: has the market gone too far?

I think it has.

The valuation has changed dramatically

WiseTech was once priced for a lot of success.

That made the shares vulnerable when sentiment turned. A high-growth stock can fall hard when investors become more cautious, and WiseTech has certainly felt that pressure.

But the current valuation now looks really interesting to me.

According to CommSec, consensus estimates are for earnings per share of 92.8 cents in FY26, $1.45 in FY27, and $2.19 in FY28.

At the current share price, that puts WiseTech on a price-to-earnings ratio of around 34 times FY26 earnings, 22 times FY27 earnings, and just over 14 times FY28 earnings.

That is the part that catches my attention.

A FY26 multiple in the 30s still requires growth. But if WiseTech gets anywhere near the FY28 consensus forecast, the valuation starts to look unusually low for a global software business with its market position.

A powerful role in global trade

The reason I still like WiseTech is the problem it solves.

Global trade is full of friction. Goods move through ports, warehouses, customs systems, carriers, freight forwarders, importers, exporters, and regulators. Every shipment can involve documents, time zones, compliance checks, pricing, tracking, and a long chain of handovers.

That is exactly the kind of environment where good software can become valuable.

WiseTech’s CargoWise platform helps logistics companies run more of that complexity through one system. The more deeply software is embedded in daily operations, the harder it can become to replace.

I also like the ambition of the company. WiseTech wants to be the operating system for global trade and logistics. That is a big goal, but it is also the kind of market where scale, product depth, compliance capability, and integration can matter enormously.

The company says it serves more than 22,000 logistics companies and other industry participants across 193 countries. It also notes that with the acquisition of e2open, its network has expanded to more than 500,000 connected enterprises across manufacturing, logistics, channels, and distribution.

That gives the business a large base from which to keep building.

What about the founder allegations?

There are also external matters investors will be aware of.

WiseTech recently responded to media commentary alleging an investigation into founder and Executive Chair Richard White, reportedly in a personal capacity. The company said there was no suggestion in the media commentary of an investigation into WiseTech. It also said it was not aware of any investigation as outlined in the article, and that Mr White had denied any involvement in or with human trafficking.

Those headlines are a concern and investors should not ignore governance or reputation risk.

But I think the key investment question remains the business itself. WiseTech’s customers, products, market position, and growth outlook are what should drive long-term value. If the company continues to execute, expand its platform, and grow earnings, I think the current share price could end up looking far too cheap.

Foolish takeaway

A share price fall of almost 75% can make investors nervous, and understandably so.

But WiseTech still operates in a large, complex, and increasingly digital market. Its software is used inside the daily machinery of global logistics, and consensus forecasts suggest earnings could grow strongly over the next few years.

There are plenty of risks to consider. Execution, acquisitions, valuation, governance, and market confidence all need watching. Even so, I think the current WiseTech share price offers patient investors a very attractive entry point.

For a business with this kind of global software opportunity, WiseTech shares look cheap to me.

The post Down almost 75%, are WiseTech shares really cheap? appeared first on The Motley Fool Australia.

More reading

• Is the tech recovery finally here for Xero and Wisetech shares?
• Here are the top 10 ASX 200 shares today
• Top brokers name 3 ASX shares to buy now
• Why Benz Mining, Collins Foods, WiseTech, and Xero shares are shooting higher today
• US chip stocks were smashed overnight. So why are ASX tech shares rising?

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares staged another strong rebound on Thursday, rising 2% to $117.65.

That extends the company’s gain over the past month to roughly 20%, a welcome change for long-suffering shareholders.

But the bigger picture remains far less impressive.

Despite the recent rally, CSL shares are still down about 32% in 2026 and have plunged a remarkable 51% over the past 12 months.

Not long ago, CSL was considered one of the safest long-term holdings on the ASX. It built a reputation as a dependable compounder, consistently growing earnings and rewarding patient investors. These days, however, the healthcare giant seems to lurch from one setback to another.

So what happened?

CSL’s latest update exposed the challenges

CSL’s latest market update provided a timely reminder of why investors have become so cautious.

The company now expects FY26 revenue of approximately US$15.2 billion and underlying net profit after tax and amortisation (NPATA) of around US$3.1 billion, both on a constant currency basis.

At first glance, those numbers may not appear disastrous. Dig a little deeper, however, and several headwinds become clear.

The biggest issue remains CSL Behring’s immunoglobulin business in the US. Demand for immunoglobulin products continues to grow at a healthy mid-to-high single-digit pace, which is broadly in line with management’s expectations. Unfortunately, investors in CSL shares won’t see the full benefit of that demand growth immediately.

CSL is normalising inventory levels across its distribution channels, which is expected to reduce reported revenue by approximately US$300 million.

Deteriorated prices

While CSL has successfully expanded its market share and stabilised sales volumes, pricing conditions have deteriorated. In other words, the company is selling more product but earning less from it. Management expects that dynamic to reduce revenue by roughly US$200 million.

The hits keep coming. CSL also flagged revenue impacts from conflict in the Middle East, slower-than-expected growth for gene therapy treatment HEMGENIX, and increasing competition in its iron business. Together, those factors are expected to shave another US$150 million from revenue.

As if that wasn’t enough, CSL expects to recognise around US$5 billion in impairment charges across FY26 and FY27. That’s the sort of figure that tends to make investors wince.

Still reasons for optimism

The update wasn’t entirely negative.

Management continues to forecast stronger revenue growth during the second half of FY26 for CSL Behring, supported by solid underlying demand, commercial execution, and benefits from ongoing operational improvement programs.

Meanwhile, vaccine business Seqirus is now expected to deliver a moderately stronger performance than previously anticipated.

Those positives help explain why the price of CSL shares has bounced from recent lows despite the disappointing headlines.

Is the CSL share price a buy?

Broker sentiment suggests analysts are not ready to give up on CSL shares just yet.

According to TradingView data, there have been 18 broker ratings on the stock over the past three months. Eight analysts rate CSL as a buy, while the remaining ten sit on the fence with hold recommendations.

The average price target stands at $141.53, implying potential upside of approximately 20% from current levels.

That suggests many analysts believe the worst may already be reflected in CSL’s battered valuation.

The post Once untouchable, now unloved: What’s up with CSL shares? appeared first on The Motley Fool Australia.

More reading

• $10,000 invested in CSL shares 12 months ago is now worth…
• Why I’d buy CSL and Zip shares before they recover
• New to ASX shares? Avoid these 3 beginner mistakes
• Down 54%: What should I do with my CSL shares now?
• Is this broker right about CSL shares?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BHP Group Ltd (ASX: BHP) shares have hit a rough patch after soaring to fresh record highs just last week.

The BHP share price has fallen around 11% since those highs and is down roughly 7% over the past five trading sessions. Despite the pullback, investors are still sitting on impressive gains. BHP shares remain up about 29% in 2026 and have surged approximately 62% over the past 12 months.

For comparison, the benchmark S&P/ASX 200 Index (ASX: XJO) has gained just 2% over the same 12-month period.

So, after a sharp sell-off, where do brokers see BHP shares heading next?

Why have BHP shares slumped?

The main catalyst behind the recent weakness of BHP shares was an update on the company’s massive Jansen potash project in Saskatchewan, Canada.

Following a comprehensive review of costs and timelines for Jansen Stage 2, BHP revealed that the project will be significantly more expensive than previously expected.

The company now estimates Stage 2 will require an additional US$4.9 billion to US$5.4 billion beyond earlier forecasts. That comes on top of the original US$4.9 billion budget approved in October 2023.

The $300 billion ASX mining stock also announced it expects to recognise an impairment charge of approximately US$2.3 billion relating to Jansen Stage 2 in its FY26 results.

The timeline has also slipped. First production from Stage 2 is now expected in FY2031, two years later than the previous target of 2029.

Little room for disappointment

Meanwhile, Jansen Stage 1 remains on track for first production in FY2027, although its cost estimate has also increased since the project was originally sanctioned. BHP has indicated it will provide a further update on Stage 1 costs and timing before 31 December 2026.

Importantly, this is not the first time Jansen’s projected costs have risen. Repeated budget revisions have increasingly tested investor confidence and raised questions about the reliability of management’s long-term project forecasts.

The market’s reaction may also reflect the strong run-up in BHP shares prior to the announcement. After climbing around 30% since the start of the year, expectations were high and there was little room for disappointment.

Some investors may also be locking in profits after the remarkable gains of BHP shares.

What do brokers forecast for BHP shares?

Despite the recent sell-off, analysts remain largely neutral on BHP’s prospects.

According to TradingView data, 13 of the 19 analysts covering BHP currently rate the stock as a hold. Four analysts have buy recommendations, while two rate the mining giant as either a sell or strong sell.

Among the more recent updates, DZ Bank upgraded BHP shares from sell to hold. The broker has an average price target of $65 per share, implying upside of around 11% from current levels.

The spread of analyst forecasts remains unusually wide.

The most optimistic analyst has a price target of $94.51, suggesting potential upside of about 61.5%. At the other end of the spectrum, the most bearish forecast sits at $40.97, suggesting downside of roughly 30%.

Foolish takeaway

That divergence highlights the key debate facing investors. On one hand, BHP continues to benefit from its world-class asset portfolio, substantial iron ore cash flows, and increasing exposure to copper, which could be crucial in the global energy transition. Potash also remains a potentially valuable long-term growth opportunity, even if the development timeline has stretched further into the future.

On the other hand, escalating project costs and execution risks at Jansen have introduced fresh uncertainty. For now, most brokers appear content to sit on the fence.

The post What’s next for BHP shares? Broker forecasts revealed appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• ASX 200 drops again as investors dump banks and miners
• Lendlease offloads Keyton stake in $525m deal
• Lendlease Group shares paused pending further announcement
• Corporate Travel Management updates investors on delayed FY25 results and UK remediation

Motley Fool contributor Marc Van Dinther has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Brightstar Resources Ltd (ASX: BTR) is being overlooked by investors at the moment, according to the team at Shaw and Partners, which has tipped the emerging gold producer to more than triple in value as its projects come into production.

Projects already well-progressed

Shaw and Partners analysts said that, between the company’s Goldfields and the Sandstone projects, Brightstar has a “realistic path” to producing 275,000 ounces of gold per year from FY31.

The analysts said in a note to clients this week:

In our view, the market is heavily discounting BTR’s project delivery. However, we find both projects relatively low-risk, standard WA gold operations. Goldfields has already commenced construction with first gold due in JunQ’27. Sandstone may be early-stage but has permitting and technical advantages, plus considerable Resource upside potential. Market confidence could be aided with two Resource updates, a maiden Reserve, and prefeasibility study expected in 2H CY26.

Brightstar made a final investment decision to proceed with the Goldfields project in May, saying at the time it was fully funded through to first gold following the completion of a $193 million equity raising and a US$120 million bond financing.

The project was expected to produce about 75,000 ounces of gold per year over the initial six-year mine life, generating about $1 billion.

Brightstar Managing Director Alex Rovira said regarding the project:

Today’s Final Investment Decision is a landmark moment for Brightstar. With all key approvals now secured, funding in place and the EPC contract executed with GR Engineering, we are immediately moving into full construction of the 1.5Mtpa Laverton processing plant. It marks the first major step in our TARGET200 strategy to build a multi-asset Western Australian gold producer and advance our aspiration of being a Top 10 Australian Gold Producer. We are fully funded, highly motivated and focused on executing with discipline to deliver this transformative project on time and on budget whilst continuing to unlock further value across our Goldfields and Sandstone assets.

The Shaw and Partners team said the Goldfields project posed low technical risk and believed the mine would eventually produce one million ounces of gold.

They said that at an earlier stage of the Sandstone project, they expected production to peak at 200,000 ounces per year and that the gold resource could “materially increase” in the second half of this calendar year.

Shares looking cheap

The analysts added that, looking at peer group companies, a market capitalisation of $2 billion was reasonable.

Brightstar’s current market capitalisation is $323.9 million.

Shaw and Partners has a $1.15 price target on the company’s shares compared to 28 cents currently.

The post Looking for returns of greater than 250%? One broker has tipped this ASX gold stock to fly appeared first on The Motley Fool Australia.

More reading

• Down almost 75%, are WiseTech shares really cheap?
• Once untouchable, now unloved: What’s up with CSL shares?
• What’s next for BHP shares? Broker forecasts revealed
• Is DroneShield the ASX growth share investors should be buying?
• Here’s what brokers tip for Telstra shares over the next 12 months

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

DroneShield Ltd (ASX: DRO) is one of the most talked-about growth shares on the ASX, and it is easy to see why.

Drones are becoming a bigger issue for defence forces, governments, airports, prisons, and critical infrastructure operators. That is creating more demand for technology that can detect, track, and respond to drone threats.

Despite this, DroneShield shares have been on a poor run and are now down around 60% from their high.

That combination of a serious long-term security problem and a much lower share price is what makes the stock interesting to me.

Why the market is interested

The basic investment case is easy to understand.

Drones are becoming cheaper, smarter, and more widely used. They can be useful for commercial and civilian purposes, but they can also create serious security problems.

Military forces, airports, prisons, major events, government sites, and critical infrastructure owners all have reasons to detect and respond to drones that should not be there.

That gives DroneShield a large problem to address. Its technology is designed to help customers detect, identify, track, and respond to drone threats. I think that full chain is important. It is not enough to know that a drone is nearby. Customers need useful information quickly and response options that fit the situation.

This is where strong products, software, sensors, and integration can become valuable.

The opportunity is bigger than one contract

One mistake investors can make with small defence technology companies is focusing too heavily on the next contract announcement.

Contracts are important, of course. They provide revenue, credibility, and proof that customers are willing to pay.

But I think the bigger question for DroneShield is whether it can build a repeatable sales engine.

That means turning interest in counter-drone technology into ongoing demand across different regions, customers, and use cases. It also means developing software, services, upgrades, warranties, and support that can add more depth to the revenue base.

If DroneShield can become a trusted supplier rather than a one-off equipment provider, the investment case becomes much more interesting.

What needs to go right

DroneShield still has a lot to prove. It needs to keep winning meaningful contracts, deliver products on time, maintain technology leadership, manage production, and support customers properly.

It also needs to show that revenue growth can translate into attractive margins and cash flow generation over time.

That last point is important. A strong theme can lift a share price, but long-term value usually comes from earnings. Investors will eventually want evidence that demand is not only real, but profitable.

Competition is another factor. Defence technology attracts serious players, and government customers can be demanding. DroneShield needs to keep showing that its products are useful, reliable, and worth selecting.

Why I’d buy

I would treat DroneShield as a speculative ASX growth share, so position sizing would be important.

This is not the type of stock I would put in the same basket as a mature blue-chip share. But I think the pullback has made the risk/reward more attractive for investors who can accept volatility.

The company is operating in a market where demand could remain strong for years, especially as drones become more common in conflict zones and around sensitive infrastructure. If counter-drone systems become a standard part of defence and security spending, DroneShield could have a substantial runway.

The upside could be significant if management executes well.

Foolish takeaway

DroneShield is a high-risk ASX growth share, but I think it is also one of the more compelling technology stories on the market.

The company is addressing a problem that governments and security customers cannot ignore. That gives it a strong starting point, while the share price fall of more than 60% from its high has made the valuation more interesting.

I would still want to see continued contract momentum, improving revenue quality, and evidence that scale can lead to stronger earnings. But for investors with a higher risk tolerance, I think DroneShield shares are worth buying as a small, patient position.

The post Is DroneShield the ASX growth share investors should be buying? appeared first on The Motley Fool Australia.

More reading

• Should I invest $5,000 in DroneShield shares before the end of June?
• Own DroneShield shares? Here’s some news you might have missed
• DroneShield shares lifting off on Monday amid big leadership news
• Here are the 10 most shorted ASX shares
• 8 ASX shares with 30% to 220% upside ahead: Experts

Motley Fool contributor Grace Alvino has positions in DroneShield. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telstra Group Ltd (ASX: TLS) shares rocketed higher at the start of the year, climbing around 18% to an all-time high in mid-May.

But as quickly as the telco‘s shares spiked, they cooled back down again. 

What has happened to Telstra shares?

The telco’s share price has been incredibly volatile recently, swinging between $5.41 and $4.97 over the past couple of months. At the time of writing, Telstra shares are trading at $5.14 a piece.

By early June, Telstra shares had fallen 11% from their peak. It looks like much of the shift in sentiment was investors taking their gains off the table after a huge rally.

The downturn also accelerated when a flurry of brokers updated their outlooks on the stock.

A broad softening in defensive shares, including telcos, and valuation concerns have also acted as headwinds.

Another headline that has weighed on sentiment is Telstra’s announcement of job cuts late last month. The company said it plans to cut 111 jobs as part of a restructuring of its technology division under new CEO Vicki Brady. The restructure collapses several of Telstra’s internal technology and infrastructure teams into two new divisions.

The latest headcount cut follows the telco’s announcement earlier this year that it would axe up to 650 roles as part of a restructuring and AI-driven efficiency programs.

It looks like investor confidence is still under pressure and the share price has struggled to rebound through June.

The question now is, what’s next?

Are the telco’s shares a buy, sell or hold?

The outlook over the next 12 months is split.

Market Index data shows the majority of brokers have a buy rating on Telstra shares. The $5.50 average target price implies a potential 7% upside ahead.

But analysts on TradingView data are a lot more reserved. All 10 analysts have a hold rating on Telstra’s shares, but their target prices vary significantly. The average $5.25 target price implies a potential 2% upside at the time of writing.

But some forecast the shares to rise 8% to $5.57, and others expect them to fall further by around 11% to $4.60 apiece.

Macquarie thinks Telstra shares are trading close to fair value. The broker downgraded its rating to a hold earlier this month and shaved its price target on Telstra shares to $5.57. Based on the current share price of $5.14, the price target suggests potential upside of around 8%.

The team at Shaw and Partners give Telstra a sell rating. The broker said it thinks the stock has been trading at elevated levels and was pushed higher by its defensive appeal. But it adds that underlying growth is limited, and the dividend yield is becoming less attractive.

The post Here’s what brokers tip for Telstra shares over the next 12 months appeared first on The Motley Fool Australia.

More reading

• Want passive income? These 3 ASX dividend stocks could deliver
• How much is needed in superannuation to target an $11,000 monthly passive income?
• How I’d build $50,000 of ASX passive income
• There are still some well-priced ASX dividend shares. Here’s where to look
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pro Medicus Ltd (ASX: PME) has done something it has rarely done at this scale before.

The company has signed a binding Heads of Agreement with Echo IQ Ltd (ASX: EIQ), a Sydney-based AI cardiology company, to expand its AI-driven cardiology solutions and broaden its commercial reach in the United States.

On paper, this is a small transaction for a company with a market capitalisation in the tens of billions.

The potential that lies underneath is what deserves attention.

What the Pro Medicus AI cardiology deal involves

Pro Medicus will make an initial $10 million investment in Echo IQ through secured convertible notes. The company retains the option to invest a further $10 million once Echo IQ’s heart failure algorithm, EchoSolv HF, receives clearance from the US Food and Drug Administration.

Pro Medicus also becomes the proposed US reseller of Echo IQ’s EchoSolv product suite. This should plug an AI-powered cardiac diagnostic tool directly into the same hospital network that already runs its Visage 7 imaging platform.

CEO Sam Hupert framed the move as part of a deliberate strategy, stating:

In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ’s technology. This is in line with our AI strategy of offering a curated suite of algorithms that will be a mixture of algorithms created by us, those created in conjunction with our clinical partners and third party algorithms such as Echo-IQ.

Definitive legal documentation is still being finalised, with completion expected within the coming weeks.

Why this deal matters more than its size suggests

Pro Medicus has spent the past 18 months landing landmark Full Stack contracts with major US health systems. The company’s cardiology modules are increasingly attached at the point of first sale.

Bolting Echo IQ’s AI diagnostic layer directly onto Pro Medicus’ existing distribution network gives Pro Medicus a capability it does not have to build in-house, sitting natively alongside the workflow its customers already use every day.

This deal positions Pro Medicus as acquiring a low-cost option on AI-led cardiology imaging without diluting its own research and development.

The more pessimistic view states that every legacy imaging vendor in North America is now racing to add its own AI partners. This may narrow the window in which a reseller deal like this one carries exclusive competitive value.

What it means for Pro Medicus shares

Pro Medicus shares were up 3.5% to $185.30 on the news, adding to a rally that has lifted the stock roughly 50% since mid-May. Year-to-date, however, shares still remain down.

This partial recovery follows a difficult few months for the stock. This downturn was driven by broader fears that AI would disrupt rather than enhance imaging software businesses.

This deal is a direct rebuttal to that fear. Pro Medicus is not being disrupted by AI cardiology tools. Rather, it is bringing them in-house and reselling them to its own customer base.

What it means for Echo IQ shareholders

The reaction in Echo IQ shares has been even more dramatic.

Echo IQ shares jumped 28% to a record high of $1.58.

Echo IQ CEO Dustin Haines called the deal:

A transformational milestone for Echo IQ and a significant validation of both our technology and long-term commercial strategy, while also providing exceptional financial flexibility to accelerate our commercialisation activities in the US.

For a small-cap AI company, validation and distribution from one of Australia’s most successful healthcare technology exporters is about as strong an endorsement as the market could ask for.

Foolish takeaway

The dollar value of this deal is immaterial to Pro Medicus’s balance sheet.

The strategic message is not.

By investing in and reselling third-party AI cardiology technology rather than treating it as a competitive threat, Pro Medicus is reinforcing the thesis that AI strengthens its moat rather than eroding it.

For a stock that spent the first half of 2026 being sold down on exactly the opposite fear, that distinction is the real reason this deal matters.

The post Pro Medicus just struck a revolutionary AI cardiology deal. Here’s why that matters appeared first on The Motley Fool Australia.

More reading

• Why is everyone talking about Mineral Resources, A2 Milk and Pro Medicus shares on Thursday?
• Why A2 Milk, EchoIQ, Lendlease, and Qantas shares are racing higher today
• A deal with Pro Medicus has turned this ASX biotech into a 10-bagger, up more than 30% today
• Pro Medicus shares jump again as AI deal adds fuel to 40% rally
• Pro Medicus signs Echo IQ deal to boost AI cardiology offering

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Superannuation is a popular and tax-effective way for working Aussies to build a long-term passive income for their future.

Of course, the catch is that you can’t access your funds until you reach your preservation age, typically around 60. You’ll also need to meet the conditions of release.

But by investing early, you can benefit from lower tax rates, compounding, and then eventually a retirement lifestyle boosted by a tax-free passive income.

The question is, how much do you need in your superannuation to receive the passive income you want when you’ve retired?

Let’s break it down, using $4,000 per month as an example.

How much do I need in my superannuation to get $4,000 of monthly passive income?

If you want to earn $4,000 in passive income every month from the money saved in your superannuation, that equates to $48,000 per year in dividend payments.

To work out the superannuation balance you’d need to get that, you’ll need to divide your annual passive income by the dividend yield.

The catch is that the figure varies widely depending on the dividend yield of the ASX shares you have in your portfolio.

For example, a portfolio with a dividend yield of around 6% only needs to be around half the size of one with a dividend yield closer to 3% to generate the same level of dividend income.

Let’s break it down further.

To earn $48,000 in annual passive income from a portfolio with a dividend yield around 3%, you’d need $1.6 million.

But to earn the same amount from a portfolio with a dividend yield closer to 4%, you’d need more like $1.2 million.

Then you’d need closer to $960,000 in a portfolio with a 5% dividend yield to earn the same amount.

If the yield is 6%, you’d need less, at around $800,000.

To get the same $48,000 of annual passive income from a portfolio with a 7% dividend yield, you’d need around $685,714. 

And if the portfolio’s dividend yield is closer to 8% or 9%, the portfolio size could be more $600,000 or $533,333, respectively.

And so on… 

As you can see, as your dividend yield increases, the superannuation balance needed to earn the same level of passive income goes down.

What ASX shares can I get around these dividend yields?

There is a wide range of high-quality ASX dividend shares available for superannuation investments, with yields varying significantly. 

But here are a few of my favourites to get you started.

Lower yielding ASX dividend-paying shares such as Wesfarmers Ltd (ASX: WES), Woolworths Group Ltd (ASX: WOW), and Washington H. Soul Pattinson and Co Ltd (ASX: SOL) are solid and reliable shares that offer a yield of around 2% to 3%.

For a mid-range yielding ASX dividend option, I’d look at defensive assets like Telstra Group Ltd (ASX: TLS) or Transurban Group (ASX: TCL), and blue-chip majors like BHP Group Ltd (ASX: BHP) and Commonwealth Bank of Australia (ASX: CBA), which pay a dividend of around 3% to 4%.

For a higher 5% to 6% dividend yield, I’d look at reliable payers like APA Group (ASX: APA), Metcash Ltd (ASX: MTS), or Origin Energy Ltd (ASX: ORG).

If you want to take on more risk and go for a much higher-yielding ASX stock, my picks would be something like IPH Ltd (ASX: IPH), the BetaShares Australian Top 20 Equities Yield Maximiser Complex ETF (ASX: YMAX), or the Metrics Income Opportunities Trust (ASX: MOT). These typically yield around 9% or more.

The post How much do I need in my superannuation to get $4,000 per month in passive income? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Age pension income and asset test limits to rise next week
• ASX 200 drops again as investors dump banks and miners
• 3 reasons to buy the rebound in JB Hi-Fi shares today
• Crude oil falls below US$70 as ASX energy shares sell-off

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group, Washington H. Soul Pattinson and Company Limited, and Wesfarmers. The Motley Fool Australia has positions in and has recommended Apa Group, Telstra Group, Transurban Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended BHP Group, IPH Ltd , and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• ASX 200 drops again as investors dump banks and miners
• 3 reasons to buy the rebound in JB Hi-Fi shares today
• Lendlease shares jump 6% after $525 million deal. Is the worst over?
• Why A2 Milk, EchoIQ, Lendlease, and Qantas shares are racing higher today
• Lendlease offloads Keyton stake in $525m deal

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block, Lovisa, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Lovisa and Premier Investments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.